Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale.</li><li>Recent, Cara Therapeutics' management announced a focus shift toward its most promising project, oral difelikefalin for treating notalgia paresthetica (NP), a chronic neuropathic condition with no currently approved therapies.</li><li>The reallocation of resources toward this program enables Cara Therapeutics to extend its cash runway into 2026, potentially covering all crucial value inflection milestones for the NP program.</li></ul>

Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale.Recent, Cara Therapeutics' management announced a focus shift toward its most promising project, oral difelikefalin for treating notalgia paresthetica (NP), a chronic neuropathic condition with no currently approved therapies.The reallocation of resources toward this program enables Cara Therapeutics to extend its cash runway into 2026, potentially covering all crucial value inflection milestones for the NP program.

Cara Therapeutics Exploring A Potential Sale But Can It Really Get Acquired? - Financial Forecasts

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based advance. As long as there are no significant negative market developments, a buy-the-dip mentality is warranted. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary, Health Care, and Transportation: Hotels &amp; Resorts, Large/Mid-Cap, Hospitals, and Vehicle Rentals/Leasing.</p>

As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based advance. As long as there are no significant negative market developments, a buy-the-dip mentality is warranted. In today’s report we highlight attractive Groups and stocks within Consumer Discretionary, Health Care, and Transportation: Hotels &amp; Resorts, Large/Mid-Cap, Hospitals, and Vehicle Rentals/Leasing.

United States

Cara Therapeutics, Inc. develops therapeutics. The Company offers novel drugs for the treatment of human diseases associated with pain and inflammation. Cara Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cara Therapeutics (CARA US)

Cara Therapeutics Exploring A Potential Sale But Can It Really Get Acquired? - Financial Forecasts

Cara Therapeutics has been trending all over the internet after the company recently decided to explore a potential sale. Recent, Cara...

Baptista Research

U.S. Equity Strategy: Taking a Breather

As the broad market takes a breather, the weight of the evidence continues to support our belief that we are in the early stages of a broad-based...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)